Objectives The use of hormone therapy (HT) for hot flushes has changed dramatically over the past five decades.
Introduction
In Sweden, between one half and two thirds of women report hot flushes (HF) around the time of menopause (1, 2). Hot flushes and night sweats often cause discomfort and may negatively impact quality of life (3, 4) . The gold standard for treating HF is hormone therapy (HT) (5) , which reduces the flushes by 75% (6) . The use of HT has changed dramatically over the past 50 years. Results from several observational studies reported beneficial effects of long-term HT use leading to subsequent increased use (7) (8) (9) . Then findings from the WHI-(10), HERS- (11) and MWS-studies (12) showed that HT had neither primary (10) nor secondary (11) preventive effects on cardiovascular disease and that the breast cancer risk was increased more than previously expected (12) during long-term use of HT. This led to changed recommendations and decreased use of HT.
Since 2002, new studies, some based on re-analyses of HERS and WHI, have shown that HT probably is safe when used by healthy women for a limited number of years around menopause (13, 14) . Alternative treatments for HF including clonidine, selective serotonin reuptake inhibitors (SSRIs), relaxation therapies, and acupuncture have been associated with decreased HF in menopausal women, both with and without breast cancer (15) (16) (17) . However, none of these treatment alternatives seem to be as effective as HT (18) (19) (20) . Observational studies have shown that postmenopausal women who exercise regularly have a lower occurrence of flushes (21, 22) but prospective studies have not yet shown evidence (23) .
It seems that middle-aged women have limited knowledge about the menopausal transition and HT (24, 25) , which makes it difficult for them to evaluate the alternative choices of treatment.
The objectives of this study consisted of two parts;
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The aim of part I was to describe the use of HT over the last decade in Sweden, particularly in Östergötland County and the municipality of Linköping, in women undergoing the menopausal transition.
In part II the aim was to analyse the data on HF and the use of HT and alternative treatments in Linköping and Östergötland collected by means of a questionnaire sent in 2010 to women aged 47-56. The questionnaire also included questions about the women's knowledge of the climacteric period and HT. In addition, the aim was to compare data from this questionnaire with data from previous studies made in the same geographic area.
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Material and Methods:
Part I
Data from the Swedish Prescribed Drug Registry
The Swedish Prescribed Drug Registry at the National Board of Health and Welfare contains information on all prescribed drugs dispensed at pharmacies in Sweden (26) . It was established in 1999 and since July 2005 the full personal identification number has been included for every entry. The registry covers the entire population in the country (full patient identity data are missing for <0.3% of the total amount of dispensed drugs measured in defined daily doses (DDD)).
DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults and is assigned to every drug by the WHO Collaborating Centre for Drug Statistics Methodology, Norway. For every single dispensation the amount of drugs dispensed measured in DDD is registered in the Swedish Prescribed Drug Registry based on the last available DDD-definition at the time of data-extraction (27, 28) . Aggregated volumes of dispensed drugs are routinely calculated by the National Board of Health and Welfare as DDD per 1,000 women and year for each geographic area, based on mid-annual figures from the national census provided by Statistics Sweden.
Data were extracted for the country as a whole, the county of Östergötland and the municipality of Linköping. The county has a population of almost 430,000 inhabitants with 150,000 residing in Linköping.
Drugs for hormone treatment of climacteric disorder were defined as per oral and transdermal products within G03CA03 estradiol (excluding low dose products and drugs for local treatment); G03CA57 conjugated estrogens; G03CX01 tibolone; G03FA01 norethisterone and estrogen, fixed; G03FA12 medroxyprogesterone and estrogen, fixed; G03FA17 drospirenone and estrogen, G03FB05 norethisterone and estrogen, sequential; G03FB06 6 medroxyprogesterone and estrogen, sequential; G03FB09 levonorgestrel and estrogen, sequential; and G03FB11 trimegestone and estrogen, sequential.
Part II
Cross-sectional study performed in 2010
A questionnaire included questions regarding demography, climacteric symptoms, menopausal status, HF, vaginal dryness, HT-use, use of alternative treatments, and questions regarding treatment needs, among other questions. The questionnaire was sent in 2010 to a random sample of 2,000 women (200 women in every age group from 47 to 56 years) living in the county of Östergötland, Sweden. Names and addresses were extracted from the national population registry. A cover letter was included with information about the aim of the study and emphasized that participation was voluntary.
The women were asked to report the frequency of HF during the preceding two weeks. The response choices were: "no flushes", "yes, flushes at least a few times during the last two weeks", "yes, flushes a few times per week" and "yes, daily flushes". The response choices concerning the severity of HF were: "no bother", "mildly bothered"; i.e. feeling of warmth but not associated with sweating and not interrupting the current activity, "moderately bothered"; i.e. feeling of warmth combined with sweating, but not interrupting the current activity and "severely bothered"; i.e. as being more bothered when the activity is interrupted, for example by opening a window, drinking something cold, readjusting clothing, waking up during the night.
The questionnaire was modified from previously used and validated questionnaires developed by us (29) (30) (31) . To test comprehension, six women, 47-56 years old, were asked to answer the questionnaire in writing. These women were thereafter personally interviewed, after which the questionnaire was modified in order to make it easier to understand. To evaluate the test-retest stability (reproducibility) the questionnaire was sent to 20 women aged between 47 and 56 years of age. After two weeks the same women, without knowing beforehand, were sent the same questionnaire and asked to answer it again. We analyzed the test-retest stability for 15 questions about demography, menopausal status, vaginal complaints and treatment alternatives for HF. The questions were answered twice by 19 of the 20 women (totally 285 duplicate questions), and 95% of the questions were answered identically the first and second time.
The questionnaires were coded, which enabled us to send a reminder to women who had not answered within three weeks. After the questionnaires were decoded, the data were optically scanned. Optical scanning was checked manually and not until the first 10 questionnaires had shown total agreement between optical and manual reading was the procedure accepted.
Results from previous studies made in the same area on postmenopausal women. 
Statistics
Optically scanned data were exported and analysed by Statistica version 10, Stat Soft Inc for Windows. Descriptive statistical methods were used such as frequency tables and crosstabulation. To test differences between groups Pearsons χ 2 test was used, p<0.05 was considered significant.
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The frequency of answered questions varied within the questionnaire and the actual frequency of answers for each question is reported. Missing data for each variable was handled as lost data.
Ethics
All questionnaire data were handled confidentially. A letter enclosed with the questionnaire informed the women about the study. By answering the questionnaire the women gave 
Part II
General results:
After one reminder and exclusion of uncompleted questionnaires the response rate was 66.1 % ( Figure 2 ). Demographic data on the 1,314 eligible women are presented in table 1.
In the whole study group (n=1,314), 6.7% (n=88) of the women were reported as having had hysterectomies and 1.7% (n=22) reported as having had bilateral oophorectomy. 
Hot flushes
In women not using HT (n=1,229; missing n=13) HF were reported by 51% (n=627). Thirtyfour percent (n=423) reported HF on some occasions each week and 17% (n=204) reported daily HF. The prevalence of HF was highest in the oldest age group (p<0.001). About half of the women who had any HF and were not using HT reported moderate severity of HF (n=307/627); 18.7% (n=117/627) reported severe complaints and about one third had mild complaints (n=205/627).
About one fourth of the women who had HF (n=157) reported that they had sought advice due to symptoms related to the climacteric period. Women with moderate HF were more inclined to seek help (47%) than women with severe HF (33%) (p<0.001).
More than half of the women (58%) had seen a gynaecologist because of the HF, 22% had sought help at pharmacies or health food stores, and 14% had seen a primary care physician.
HF in postmenopausal women (n=497; missing n=40) are shown in figure 3.
Analyses in postmenopausal women not using HT
Natural remedies, herbs and/or food supplements were used by 8.3% (n=28) of postmenopausal women with HF not using HT (n=339). Almost one third (28.2%, n=96) of these women used alternative treatments (one or a combination of acupuncture, physical activity, relaxation, mindfulness, changes in food-habits and/or other lifestyle changes (table   II) .
In postmenopausal women who reported severe HF about 60% stated "need of treatment" for HF compared with 2.9% in women who reported mild complaints (p<0.001) (table III) . In women with severe complaints who stated "need for treatment", the reasons for refraining from any treatment were fear of side effects (n=14; 38%), had not yet contacted a gynecologist (n=11; 30%), discontinued because of side effects (n=6, 16%), and had been advise not to have treatment (n=6; 16%).
Almost one third (n=95) of postmenopausal women not using HT stated that they would be positive to HT if therapy were to be considered harmless. This was more often stated by women with severe complaints (67.2%) compared to women with moderate (26%) and mild (12.5%) complaints of HF (p<0.001).
Knowledge about the climacteric period and potential treatments
Of all the women in this study (n=1,314), 53 % stated that they thought they had insufficient knowledge of the menopausal transition and treatment options, about the same percentage (54%) of women with HF and not using HT (n=607). Thirty five percent of the women who used HT (n=69) also said they had insufficient knowledge.
Almost half (49%) of women who had sought help (n=187) for climacteric complaints did not think that their knowledge of the menopausal transition and its potential treatment was sufficient.
Data from previous studies
In the previous studies (1, 30, 32-34) both perimenopausal and postmenopausal women were included. Hammar et al (1) reported that about half of the women in the study-group were interested in receiving estrogens if the treatment had no side-effects, and even about one fourth of women who had never experienced HF expressed the same view.
HF are reported at different frequencies in these studies (1, 30, 32-34) ranging between 13-61%, depending on age of the women, severity of HF and also on the percentage of women using HT (table IV) . Use of HT and natural remedies is also shown in table IV.
Discussion
In this current study only 5.5% of women, 47-56 years old in the county of Östergötland, Sweden, used HT in 2010 at the time of responding to the survey (point prevalence). This corresponds well with the period prevalence for 2010 of 57 per 1,000 women (or 5.7%) in the same age interval in Östergötland being treated with HT as reported in the Swedish Prescribed Drug Registry.
Interestingly, almost twice as many women in the present study reported use of
Complementary and Alternative Medicine (CAM) in order to reduce HF compared to women using HT. In a group of Italian women aged 45-65, almost half had used some kind of treatment for menopausal symptoms during the preceding year. About 10% of women who had used other remedies also had used HT. It was shown that more than one of four women in this group had used CAM remedies, mostly herbal products and soy, in the diet (35) . Women thus seem to be more prone to try natural remedies, herbs and food supplements than to use HT for relief of climacteric problems. It should be emphasized that such treatments have not been very well studied or regulated and studies explicitly designed to find negative long-term effects on, for example, breast-tissue and/or endometrium have not yet been published.
Furthermore some species of red clover may interfere with coagulation and may cause herbdrug interactions, although these data are not conclusive (36) . In 2006 EMEA published a warning advising against unrestricted use of Black cohosh (37). Recently a meta-analysis of RCT's on black cohosh showed no evidence of hepatotoxicity (38) . Since CAM remedies are not regulated as drugs they can be bought over the counter in pharmacies and convenience stores, without prescription and information about adverse effects, which may lead to a false sense of safety (19) .
Perhaps HT-use is still seen as something to be avoided because of the results from WHI-(10), HERS-(11) and WMS-(12) studies. This view is supported by our finding that one third of the postmenopausal women not on HT said that they would be positive to HT if there was evidence that the treatment is harmless. An even greater percentage (more than 60%) of women with severe complaints took this position. In postmenopausal women with severe HF, six of ten women stated that they needed treatment for flushes, and that the most common reason for not using HT was fear of side effects. Also the more frequent and severe flushes the woman reported; the greater was their expressed need for therapy. We suspect that many women have a fear of HT that is not evidence based, and these women need to be given more individualized and differentiated information. More than half of all women in the study and even one third of women on HT stated that they had insufficient knowledge about the climacteric period and its treatment options. Probably the lack of information and knowledge of HT and its risks and benefits lead the women to try other therapies such as natural remedies, herbs and food supplement since they consider these treatments safer. Recent metaanalyses show positive evidence that phytoestrogens are effective in alleviating menopausal symptoms, but more studies are needed (39, 40) . According to a systematic review, herbal preparations containing black cohosh cause a reduction in menopausal symptoms by 26%; but there were significant differences between trials (41). However, a
Cochrane review from 2012 stated that more studies are needed to support whether the use of black cohosh is effective for hot flushes or not (42).
It appears that more studies are needed both for evaluating the efficacy on HF and also the long-term-safety of these preparations. Other prescribed drugs, such as clonidine, SSRI, and gabapentin decrease the frequency and severity of HF but not as effectively as HT (18, 19) .
The use of these drugs was low among the women who participated in the present study, and is therefore not discussed further.
In line with previous studies (43-45) the present study showed that almost 70% of postmenopausal women not on HT reported HF, and more than one third of these had daily complaints. Thus many women report and suffer from HF without seeking medical advice, probably due to fear of side effects from HT. Reanalyses of the WHI suggest that the age of the woman at initiation of therapy is crucial, and when HT is prescribed within 4-6 years of menopause, there are probably cardio-and neuro-protective effects (13) . On the other hand a recent study suggests that women with early onset of HT after menopause are at higher risk of breast cancer than women with delayed onset (46) . Also, a meta-analysis of 23 randomized, controlled trials showed a significant reduction of cardiac events in women with early menopause using HT (47) . Other interesting findings in the risk/benefit evaluation are the possible relation between HF and increased risk of CVD (48) . Furthermore, if HT is initiated before the age of 60, a significant reduction in all-cause mortality is seen compared to mortality in the group on placebo (47) . If women were better informed about these results this might lead to a wider acceptance of estrogen therapy in postmenopausal women (49) .
One limitation is the response rate, which in our study was slightly lower (66%) than in earlier studies of women in the same area (at or above 75%) (1, 32, 34, 35) . This decline in response rates is in agreement with a general secular trend in Sweden and is not unique for Swedish studies. The declining response rate will probably decrease the response representativeness of the results, increase the bias of the trend estimates and limit the comparability of the results between population groups and surveys (50) .
On the other hand the proportion of HT users in this study was congruent with data from the Swedish Prescribed Drug Registry. This supports the interpretation that women who answered the questionnaire in this study seem to be representative of the whole population.
In the current study 10.9% of the responders had a native language other than Swedish. In the same geographical area, 15.5% of the women in the same age-group were not born in Sweden, according to data from Sweden Statistics. Women born outside Sweden might have had Swedish or one of the closely related Nordic languages as a native language. Our interpretation is that there probably is a lower response rate among immigrants and the overall results may not be used to describe with certainty the situation among this minority group.
Data from non-responders could not be collected because of the use of coded questionnaires.
We have also various numbers of missing data on single questions, despite a ninety-five percent similarity when we analysed test-retest stability before the survey. We choose to only
show the results that are given, i.e. no calculated values for missing data were included, since we consider that the results are more "true" in that way.
In conclusion, HF are common around menopause and our findings are in line with similar studies (51, 52) of menopausal women not on HT. Apparently HT-use is much lower than the prevalence of flushes and many women probably suffer unnecessarily. Women in this study seem to be more prone to use herbal remedies, food supplements and alternative treatments than to use HT. Women with severe complaints from HF stated they would be more likely to request HT if they could be assured that it does not increase the risk of serious disease. Many women have a fear of HT that is no longer justified by the most recent research. We suggest that more individualized and differentiated information should be given to women during the menopausal transition, to counteract their fear of HT, giving women with significant climacteric complaints and without contraindications of HT the possibility to make a wellreasoned decision whether or not to use HT. Questionnaire sent to women aged 47-56 years living in Östergötland, Sweden n=2,000
Number of questionnaires eligible for analyses n=1,314 (66.1 %)
Returned due to unknown addresses n=11
Number of returned questionnaires after one reminder n=1,326 (66.7 %)
Returned, not completed n=6 Excluded questionnaires due to inconsistent answers n=6  Mild: feeling of warmth but no sweating and not interrupting the current activity,  Moderate; feeling of warmth combined with sweating, but not interrupting the current activity  Severe; same as moderate but the activity is interrupted, for example by open a window, drink something cold, readjust the clothing, wake up during the night. † Have treatment other than HT (not specified)
